IP Library › Granted Patent US 11,299,484
Granted Patent B2
US 11,299,484 · App. 17/021,759 · Granted Apr 12, 2022

Inhibiting fatty acid synthase (FASN)

Inventors: Matthew W. Martin (Arlington, MA); Mary-Margaret Zablocki (Revere, MA); Scot Mente (Watertown, MA); Christopher Dinsmore (Newton, MA); Zhongguo Wang (Lexington, MA); Xiaozhang Zheng (Lexington, MA)
Assignee: FORMA Therapeutics, Inc.
C07D405/14C07D221/20C07D405/06C07D409/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,299,484
App. No.
17/021,759
Granted
Apr 12, 2022
Kind
B2
Abstract

The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

Claims (70)

1. A method for preparing a compound of formula (VII-A):

or a pharmaceutically acceptable salt thereof, wherein:

Ring B is phenyl, fused bicyclic 8-10 membered aryl, or fused bicyclic 8-10 membered heteroaryl containing 1-2 heteroatoms independently selected from the group consisting of O, N, and S;

R 1 is 3-membered cycloalkyl optionally substituted with —OH, or 5-membered heterocyclyl containing 1-3 heteroatoms independently selected from the group consisting of O, N, and S;

each R d is independently halogen, —CO 2 H, —OR 3 , SO 2 NHCOR 3 , C 1-3 aliphatic, or 5-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S; and

each R 3 is independently hydrogen or C 1-3 alkyl;

comprising:

treating a compound of formula (A):

with a compound of formula (B):

Ar—X   (B)

to afford a compound of formula (C):

wherein:

PG is hydrogen or Boc;

X is halogen; and

Ar is a substituted phenyl, fused bicyclic 8-10 membered aryl, or fused bicyclic 8-10 membered heteroaryl containing 1-2 heteroatoms independently selected from the group consisting of O, N, and S; and

converting the compound of formula (C) to the compound of formula (VII-A), or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein said treating the compound of formula (A) with the compound of formula (B) is performed in the presence of a palladium catalyst and a base.

3. The method of claim 1 , wherein the compound of formula (VII-A) is

4. The method of claim 3 , wherein the compound of formula (C) is

5. The method of claim 4 , wherein the compound of formula (A) is

and

the compound of formula (B) is

6. The method of claim 4 , wherein said converting the compound of formula (C) to the compound of formula (VII-A) comprises:

treating the compound of formula (C) with trifluoroacetic acid to afford a compound of formula (D)

coupling the compound of formula (D) with 1-hydroxycyclopropane-1-carboxylic acid to afford a compound of formula (E)

treating the compound of formula (E) with trifluoroacetic acid to afford a compound of formula (F)

and

separating enantiomers of the compound of formula (F) by chiral HPLC to afford the compound of formula (VII-A).

7. The method of claim 1 , wherein the compound of formula (VII-A) is

8. The method of claim 7 , wherein the compound of formula (C) is

9. The method of claim 8 , wherein the compound of formula (A) is

and

the compound of formula (B) is

10. The method of claim 8 , wherein said converting the compound of formula (C) to the compound of formula (VII-A) comprises:

treating the compound of formula (C) with trifluoroacetic acid to afford a compound of formula (D)

coupling the compound of formula (D) with 1-hydroxycyclopropane-1-carboxylic acid to afford a compound of formula (E)

treating the compound of formula (E) with trifluoroacetic acid to afford a compound of formula (F)

and

separating enantiomers of the compound of formula (F) by chiral HPLC to afford the compound of formula (VII-A).

11. The method of claim 1 , wherein the compound of formula (VII-A) is

12. The method of claim 11 , wherein the compound of formula (C) is

13. The method of claim 12 , wherein the compound of formula (A) is

and

the compound of formula (B) is

14. The method of claim 12 , wherein said converting the compound of formula (C) to the compound of formula (VII-A) comprises:

coupling the compound of formula (C) with 1-hydroxycyclopropane-1-carboxylic acid to afford the compound of formula (VII-A).

15. The method of claim 1 , wherein the compound of formula (VII-A) is

16. The method of claim 15 , wherein the compound of formula (C) is

17. The method of claim 16 , wherein the compound of formula (A) is

and

the compound of formula (B) is

18. The method of claim 16 , wherein said converting the compound of formula (C) to the compound of formula (VII-A) comprises:

treating the compound of formula (C) with sodium azide and zinc chloride to afford a compound of formula (D)

treating the compound of formula (D) with trifluoroacetic acid to afford a compound of formula (E)

or a trifluoroacetate salt thereof;

coupling the compound of formula (E), or a trifluoroacetate salt thereof, with (2R)-tetrahydrofuran-2-carboxylic acid to afford a compound of formula (F)

and

separating diastereomers of the compound of formula (F) by HPLC to afford the compound of formula (VII-A).

19. The method of claim 1 , wherein the compound of formula (VII-A) is

20. The method of claim 19 , wherein the compound of formula (C) is

21. The method of claim 20 , wherein the compound of formula (A) is

and

the compound of formula (B) is

22. The method of claim 20 , wherein said converting the compound of formula (C) to the compound of formula (VII-A) comprises:

treating the compound of formula (C) with sodium azide and zinc chloride to afford a compound of formula (D)

treating the compound of formula (D) with trifluoroacetic acid to afford a compound of formula (E)

or a trifluoroacetate salt thereof;

coupling the compound of formula (E), or a trifluoroacetate salt thereof, with (2R)-tetrahydrofuran-2-carboxylic acid to afford a compound of formula (F)

and

separating diastereomers of the compound of formula (F) by HPLC to afford the compound of formula (VII-A).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2020
From: MARTIN, MATTHEW W.; ZABLOCKI, MARY-MARGARET; MENTE, SCOT; DINSMORE, CHRISTOPHER; WANG, ZHONGGUO; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 054074/0620 →
Priority Claims (1)
TW 108136774 · Oct 9, 2019 · national
Continuity (3)
Continuation 16598481 · Oct 10, 2019
Provisional Application 62744071 · Oct 10, 2018
Related Publication 20210024508A1 · Jan 28, 2021
Cited By (3)
US 12,577,234 US 12,600,726 US 12,715,862